Therefore, the clinical trial was expanded, screening and enrolling NSCLC stage III and IV ALK-positive patients in a large cohort treated with the maximum tolerated dose (MTD) of crizotinib 250 mg twice daily in a 28-day cycle. Here, ALK is linked to non-small cell lung carcinoma.